



OS-14-01

Attorney Docket No. 0575/52876/JPW/JML

Inventor

Total Pages 2

Express Mail Label No. EK 873 626 795 US

1646

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ASSISTANT COMMISSIONER FOR PATENTS
Box CPA
Washington, D. C. 20231

RECEIVED

MAY 16 2001

TECH CENTER 1600/2900

CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL

Sir:

This is a request for filing a CONTINUATION DIVISIONAL application under 37 CFR 1.53(d) continued prosecution application (CPA) of pending prior application Serial No. 08/905,709 filed on August 5, 1997 entitled A METHOD TO PREVENT ACCELERATED ATHEROSCLEROSIS USING (sRAGE) SOLUBLE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS.

#19
J. Q. J.
6/5/01

1. Enter the unentered amendment previously filed on _____ under 37 CFR 1.116 in the prior nonprovisional application.
2. A preliminary communication is enclosed.
3. This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53 (d)(4).

a. DELETE the following inventor(s) named in the prior nonprovisional application:

b. The inventor(s) to be deleted are set forth on a separate sheet attached hereto.

4. A new power of attorney or authorization of agent (PTO/SB/81) is enclosed.

5. Information Disclosure Statement (IDS) is enclosed:

- a. PTO-1449
- b. Copies of IDS Citations

6. Small entity status:

- a. A small entity statement is enclosed.
- b. A small entity statement was filed in the prior nonprovisional application and such status is still proper and desired.
- c. Is no longer claimed.

The filing fee is calculated as follows:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT

					Rate			Fee	
	Number Filed		Number Extra*		Small Entity	Other Entity		Small Entity	Other Entity
Total Claims	25 -30	=	0	x	\$ 9	\$ 18	=	\$ 0	\$
Indep. Claims	2 - 5	=	0	x	\$ 40	\$ 80	=	\$ 0	\$
Multiple Dependent Claims Presented: Yes <u> </u> No <u>X</u>					\$135	\$270	=	\$ 0	\$
If the difference in column 1 is less than zero, enter "0" in column 2					Basic Fee		\$ 355	\$ 710	
					Total Fee		\$ 355.00		

7. X A check in the amount of \$ 535.00 to cover the filing fee and the Information Disclosure Statement fee.

8. X The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the following or credit any overpayment to Deposit Account No. 03-3125.

X Filing fees under 37 C.F.R. § 1.16.

X Patent application processing fees under 37 C.F.R. §1.17.

 The issue fee set in 37 C.F.R. §1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. §1.311(b).

9. X Three copies of this sheet are enclosed.

10. X Other (identify) Request For Continued Prosecution Application, Supplemental Information Disclosure Statement including Exhibits 1-32, and an Express Mail Certificate of Mailing bearing label No. EK 873 626 795 US dated May 11, 2001.

May 11, 2001
Date

Respectfully submitted,



John P. White,
Registration No. 28,678
Jane M. Love,
Registration No. 42,812
Attorneys for Applicant
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, NY 10036
Tel.: (212) 278-0400



Dkt. 05/5/52876/JPW/JML

IN THE UNITED STATES RECEIVING OFFICE (RO/US)

Applicant : David Stern and Ann Marie Schmidt

Serial No.: CPA of 08/905,709 Examiner: E. Lazar-Wesley

Filed : August 5, 1997 Art Unit: 1646

For : A METHOD TO PREVENT ACCELERATED ATHEROSCLEROSIS
USING (sRAGE) SOLUBLE RECEPTOR FOR ADVANCED
GLYCATION ENDPRODUCTS

1185 Ave of the Americas
New York, New York 10036
May 11, 2001

Assistant Commissioner for Patents

Washington, D.C. 20231

Box: CPA

SIR:

EXPRESS MAIL CERTIFICATE OF MAILING
FOR ABOVE-IDENTIFIED APPLICATION

"Express Mail" mailing label number: EK 873 626 795 US

Date of Deposit: May 11, 2001


I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, BOX: CPA, Washington, D.C. 20231

Printed Name: Jane M. Love

Respectfully submitted,

Jane M. Love

John P. White
Registration No. 28,678
Jane M. Love
Registration No. 42,812
Attorney for Applicant
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400



0575/52876/JPW/JML

TECH CENTER 1600/2900

MAY 16 2001

RECEIVED

UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : David Stern and Ann Marie Schmidt # 20

Serial No. : CPA2 of 08/905,709 Examiner: E. Lazar-Wesley

Filing Date : March 23, 2000 Art Unit: 1646

For : A METHOD TO PREVENT ACCELERATED
ATHEROSCLEROSIS USING (SRAGE) SOLUBLE
RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS

Date of Notice
of Allowance: February 14, 2001 Issue Batch: B87

1185 Avenue of the Americas
New York, New York 10036
May 11, 2001

Honorable Commissioner for Patents
Washington, D.C. 20231

BOX: CPA

Sir:

REQUEST FOR CONTINUED PROSECUTION APPLICATION, SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT AND PRELIMINARY AMENDMENT

This application is a continued prosecution application ("CPA") of U.S. Serial No. 08/905,709, filed March 23, 2000. A Notice of Allowance was issued by the U.S. Patent and Trademark Office on February 14, 2001 in connection with the above-identified application and therefore an issue fee is due on May 14, 2001. This CPA application is filed herewith in lieu of paying the issue fee which is due on May 14, 2001. Applicants have enclosed the \$355.00 filing fee required for filing the CPA. Thus, this CPA, Supplemental Information Disclosure Statement and Preliminary Amendment are being timely filed.

1185/2001 AMENDMENT 00000037 08905709

160.00 0P